Pancreatic Cancer Action Network (PanCAN) president and CEO Julie Fleshman, JD, MBA, contributed an article titled, “Know All of Your Options: Clinical Trials Save Lives,” to HuffPo stressing the importance of clinical trial enrollment among pancreatic cancer patients.
With news last week that the five-year survival rate for pancreatic cancer remains at 9 percent, clinical trial enrollment is more important than ever to help improve patient outcomes.
Pancreatic cancer patients who participate in clinical research have better outcomes. Every treatment available today was approved through a clinical trial. The Pancreatic Cancer Action Network strongly recommends clinical trials at diagnosis and during every treatment decision.